Antibody Therapy in Aggressive Lymphomas (original) (raw)
Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas
D Scott Wilbur
2002
View PDFchevron_right
Novel CD20 monoclonal antibodies for lymphoma therapy
Nikhil Mukhi
Journal of Hematology & Oncology, 2012
View PDFchevron_right
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma
Michael L Goris
Clinical cancer research : an official journal of the American Association for Cancer Research, 1996
View PDFchevron_right
CD22-directed monoclonal antibody therapy for lymphoma
Alessandra Cesano
Seminars in Oncology, 2003
View PDFchevron_right
Role of antibody therapy in lymphoid malignancies
Claire Dearden
British Medical Bulletin, 2007
View PDFchevron_right
Anti-CD20-based therapy of B cell lymphoma: state of the art
Niki Stavroyianni
Leukemia, 2002
View PDFchevron_right
A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts
D Scott Wilbur
View PDFchevron_right
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
D. Wilbur
Blood, 2009
View PDFchevron_right
Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab
G. Dastoli
Critical Reviews in Oncology/Hematology, 2001
View PDFchevron_right
Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas
Julia Rincon
Cancer Treatment Reviews, 2015
View PDFchevron_right
Application of anti-CD20 monoclonal antibodies in the treatment of lymphoproliferative diseases
Ivica Pejcic
Archive of Oncology, 2009
View PDFchevron_right
131 I-labelled Anti-CD22 MAb (LL2) in Patients with B-Cell Lymphomas Failing Chemotherapy
Sven-erik Strand
Acta Oncologica, 2002
View PDFchevron_right
Anti-CD20 treatment for B-cell malignancies: current status and future directions
Candice Jamois
Expert Opinion on Biological Therapy
View PDFchevron_right
The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma
Terrence J Piva, Peter Eu
Targeted oncology, 2015
View PDFchevron_right
Monoclonal antibody therapy for classical Hodgkin lymphoma
Jan Walewski
Clinical Investigation, 2013
View PDFchevron_right
Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma
Edmund Rossi
Journal of Nuclear Medicine, 2009
View PDFchevron_right
Lymphoma Immunotherapy: Current Status
Massimo Di Nicola
Frontiers in Immunology, 2015
View PDFchevron_right
Use of Ibritumomab Tiuxetan Anti-CD20 Radioimmunotherapy in a Non-Hodgkin's Lymphoma Patient Previously Treated with a Yttrium-90–Labeled Anti-CD22 Monoclonal Antibody
Abass Alavi
Clinical Lymphoma, 2003
View PDFchevron_right
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts
David Kukis
Blood, 2003
View PDFchevron_right
90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma
Jeffrey White
Proceedings of the National Academy of Sciences of the United States of America, 2015
View PDFchevron_right
Evaluation of CD20, CD22, and HLA-DR Targeting for Radioimmunotherapy of B-Cell Lymphomas
D Scott Wilbur
Cancer Research, 2007
View PDFchevron_right
Radioimmunotherapy of B-cell non-Hodgkin's lymphoma
Jacques Barbet
European Journal of Nuclear Medicine, 2001
View PDFchevron_right
Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
Martin Dyer
Journal of Clinical Oncology, 2009
View PDFchevron_right
Determination of CD20 Protein Expression in B-Cell Lymphoma Cancer & Study of ANTI-CD20 Therapy
Kashyap Raval
2017
View PDFchevron_right
Improved Outcome When B-Cell Lymphoma Is Treated with Combinations of Immunoliposomal Anticancer Drugs Targeted to Both the CD19 and CD20 Epitopes
Theresa Allen
Clinical Cancer Research, 2004
View PDFchevron_right
Radioimmunotherapy of Lymphoma: A Treatment Approach Ahead of Its Time or Past Its Sell-By Date?
Tim Illidge
Journal of Clinical Oncology, 2010
View PDFchevron_right
Preclinical study of 212Pb alpha-radioimmunotherapy targeting CD20 in non-Hodgkin lymphoma
Michel Cogné
British Journal of Cancer, 2021
View PDFchevron_right
Radioimmunotherapy of Relapsed Non-Hodgkin's Lymphoma with Zevalin, a 9~ Anti-CD20 Monoclonal Antibody 1
John Gutheil
1999
View PDFchevron_right
A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma
Alan Green
Clinical Cancer Research, 2009
View PDFchevron_right
Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19
Cornelis Melief
Cancer Immunology Immunotherapy, 1995
View PDFchevron_right
Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas
D Scott Wilbur
Blood, 2007
View PDFchevron_right
Safety and Efficacy of Radioimmunotherapy with 90Yttrium-rituximab in Patients with Relapsed CD20+ B cell Lymphoma: A Feasibility Study
Thomas Guiot
Journal of Cancer Science and Therapy
View PDFchevron_right
Pretargeted Radioimmunotherapy for B-Cell Lymphomas
D Scott Wilbur
Clinical Cancer Research, 2007
View PDFchevron_right